ClinicalTrials.gg
Active, not recruitingNCT05928416RNALSUpdated Mar 27, 2026

ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

An observational study in Amyotrophic Lateral Sclerosis, Sporadic and Amyotrophic Lateral Sclerosis, sponsored by ZIWIG. Active, not recruiting at 19 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by ZIWIG · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
653
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.

Enrollment
4th of 29
653 · median 138
Started
2023
with 10 others
Observational
29 of 132
9 open now
Primary completion
2025-11
later than 6 of 35 live
Registered
108th of 132
by date

Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 4th largest by enrollment of the 29 observational ones that give a count, is one of 11 that started in 2023, is one of 29 observational ones, reaches primary completion later than 6 of the 35 other live ones, and was the 108th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Amyotrophic Lateral Sclerosis with a site in France, or all of them as a file.
02

Study summary

RNALS is a multicentre, transversal, diagnostic and non-interventional study carried out in ALS reference centers; in order to identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and non-coding RNA contained in patients saliva.

The study population consists of patients with definite or probable amyotrophic lateral sclerosis (ALS) according to the El Escorial criteria ("ALS Subjects" group) and subjects with no neurological history (Control group).

The control group will be made up of caregivers of patients with ALS, and caregivers of patients with a pathology other than ALS.

The ALS patients concerned by the study already benefit from routine medical care in ALS expert centers in France.

The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the recommendations of the HAS, CNGOF.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis, Sporadic
  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • RNA
  • Saliva sample
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be made up with amyotrophic lateral sclerosis (ALS) patients defined or probable according to El Escorial criteria ("ALS patients" group) and patients with no medical history or neurological symptoms (Control Group).

The control group will be made up of people accompanying the patients (with or without ALS).

The ALS patients in the study already benefit from routine medical care in ALS expert centers in France. .

The patients concerned by the study are managed without modification of the care pathway, no modification of the therapeutic indications, no modification of the diagnostic examinations or follow-up necessary according to the context, which are carried out according to the recommendations of the HAS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age,
  • Patient from one of the 2 study populations:

    • Diagnosis of definite or probable ALS according to El Escorial criteria ("patients ALS" group) ;
    • Control group
  • Patient able to carry out a mouth rinse,
  • Patient affiliated to the healthcare system,
  • Patient has dated and signed the consent form,

Exclusion criteria

Exclusion Criteria:

  • Recent (\<1 month) or ongoing bacterial or viral infection,
  • Known active oral or digestive mycosis,
  • Evolving, symptomatic or obvious oral pathology,
  • Known pregnancy,
  • Patient participating in another clinical research study,
  • Patient deprived of liberty by administrative or judicial decision or under guardianship ;
  • Subject refusing to take a saliva sample;
  • For the control group: direct relationship (siblings, descendants, ascendants) with a patient included in the study;
  • For control group: medical history of neurological disease (excluding migraine).
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
653 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • SLA group

    300 patients

    Diagnostic Test: Saliva sample

  • Control group

    300 patients

    Diagnostic Test: Saliva sample

Interventions

  • Diagnostic testSaliva sample

    During the inclusion visit : * a neurological examination is taken * a saliva sample is taken

  • Diagnostic testSaliva sample

    During the inclusion visit : * a saliva sample is taken

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of the Receiver Operating Curve (ROC)

    Identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and non-coding RNA contained in the saliva.

    Time frame: Through the end of study inclusions, an average of 2 years

07

Study locations

19 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Nov 2025, 28 months.

Of 138 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2023
First posted
Jul 3, 2023
StartActual
Jul 11, 2023
Primary completionActual
Nov 18, 2025
CompletionEst.
May 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05928416
Lead sponsor
ZIWIG
Collaborators
Monitoring Force Group
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Jul 11, 2023
Primary completion
Nov 18, 2025
Completion
May 2026 (estimated)
Last update
Mar 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion